BridgeBio (NASDAQ: BBIO) CEO reports Rule 10b5-1 stock sales

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma’s Chief Executive Officer, Kumar Neil, reported indirect open-market sales of the company’s common stock on February 10–11, 2026. The transactions were executed by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he serves as co-trustee, under a Rule 10b5-1 sales plan adopted on March 31, 2025. Individual trades included, for example, 14,201 shares sold at a weighted average price of $71.8018 per share and 7,806 shares at $70.6887 per share. After these sales, the trusts continued to hold large indirect positions, including 675,686 and 4,478,447 shares, and the Form 4 notes that the reporting person disclaims beneficial ownership beyond any pecuniary interest.

Insider Trade Summary

Net Seller: 80,000 shares ($5,748,666)

Net Sell 13 txns

Insider Kumar Neil

Role Chief Executive Officer

Sold 80,000 shs ($5.75M)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,806	$70.6887	$552K
Sale	Common Stock	3,716	$71.4416	$265K
Sale	Common Stock	4,484	$72.635	$326K
Sale	Common Stock	3,994	$73.2535	$293K
Sale	Common Stock	7,860	$70.7005	$556K
Sale	Common Stock	3,775	$71.4581	$270K
Sale	Common Stock	4,404	$72.6472	$320K
Sale	Common Stock	3,961	$73.2505	$290K
Sale	Common Stock	14,201	$71.8018	$1.02M
Sale	Common Stock	5,799	$72.2823	$419K
Sale	Common Stock	14,040	$71.7953	$1.01M
Sale	Common Stock	5,960	$72.2737	$431K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 687,880 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 228,776 shares (Direct)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. Represents the weighted average sale price of the shares sold from $71.08 to $72.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Represents the weighted average sale price of the shares sold from $72.08 to $72.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $71.02 to $72.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $72.02 to $72.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $70.09 to $71.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $71.09 to $72.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $72.09 to $73.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $73.09 to $73.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $71.1 to $72.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $72.1 to $73.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $73.1 to $73.4 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

02/12/2026 - 04:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/10/2026		S⁽¹⁾		14,201	D	$71.8018⁽²⁾	701,485	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/10/2026		S⁽¹⁾		5,799	D	$72.2823⁽⁴⁾	695,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/10/2026		S⁽¹⁾		14,040	D	$71.7953⁽⁵⁾	4,504,407	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/10/2026		S⁽¹⁾		5,960	D	$72.2737⁽⁶⁾	4,498,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/11/2026		S⁽¹⁾		7,806	D	$70.6887⁽⁷⁾	687,880	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/11/2026		S⁽¹⁾		3,716	D	$71.4416⁽⁸⁾	684,164	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/11/2026		S⁽¹⁾		4,484	D	$72.635⁽⁹⁾	679,680	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/11/2026		S⁽¹⁾		3,994	D	$73.2535⁽¹⁰⁾	675,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/11/2026		S⁽¹⁾		7,860	D	$70.7005⁽⁷⁾	4,490,587	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/11/2026		S⁽¹⁾		3,775	D	$71.4581⁽¹¹⁾	4,486,812	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/11/2026		S⁽¹⁾		4,404	D	$72.6472⁽¹²⁾	4,482,408	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	02/11/2026		S⁽¹⁾		3,961	D	$73.2505⁽¹³⁾	4,478,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock								228,776	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $71.08 to $72.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. Represents the weighted average sale price of the shares sold from $72.08 to $72.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. Represents the weighted average sale price of the shares sold from $71.02 to $72.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

6. Represents the weighted average sale price of the shares sold from $72.02 to $72.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

7. Represents the weighted average sale price of the shares sold from $70.09 to $71.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

8. Represents the weighted average sale price of the shares sold from $71.09 to $72.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

9. Represents the weighted average sale price of the shares sold from $72.09 to $73.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

10. Represents the weighted average sale price of the shares sold from $73.09 to $73.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

11. Represents the weighted average sale price of the shares sold from $71.1 to $72.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

12. Represents the weighted average sale price of the shares sold from $72.1 to $73.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

13. Represents the weighted average sale price of the shares sold from $73.1 to $73.4 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BridgeBio Pharma (BBIO) disclose in this Form 4?

BridgeBio Pharma disclosed that its CEO, Kumar Neil, reported indirect open-market sales of common stock on February 10–11, 2026. The sales were executed by family trusts where he is co-trustee, rather than by him individually, and involved multiple trade sizes and prices.

How many BridgeBio (BBIO) shares were sold in one of the larger reported transactions?

One of the larger reported transactions shows the sale of 14,201 shares of BridgeBio common stock at a weighted average price of $71.8018 per share. This sale was made by the Kumar Haldea Family Irrevocable Trust, with the CEO serving as co-trustee, as part of the disclosed trading activity.

On what dates did the BridgeBio (BBIO) insider sales reported here occur?

The reported insider sales occurred on February 10, 2026 and February 11, 2026. Multiple trades were executed on each date by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, all involving BridgeBio common stock and reported as open-market sales.

Were the BridgeBio (BBIO) insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected under a Rule 10b5-1 sales plan adopted on March 31, 2025. Such plans allow pre-arranged trading of shares according to specified terms, helping separate trading decisions from day-to-day, non-public information.

Who actually held the BridgeBio (BBIO) shares involved in these reported sales?

The shares were held by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where the CEO is a co-trustee. The Form 4 notes that he disclaims beneficial ownership of these shares except to the extent of any pecuniary interest he may have.

How many BridgeBio (BBIO) shares did the trusts hold after the reported sales?

After the reported transactions, the filing shows continued large indirect holdings, including 675,686 shares in the family irrevocable trust and 4,478,447 shares in the revocable trust. In addition, 228,776 shares are listed separately under direct ownership, reflecting multiple ownership forms.